Cargando…

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

OBJECTIVE: Follistatin-like protein 1 (FSTL1) is widely recognised as a secreted glycoprotein, but its role in modulating macrophage-related inflammation during liver fibrosis has not been documented. Herein, we aimed to characterise the roles of macrophage FSTL1 in the development of liver fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Jianhua, Wang, Hao, Ni, Ming, Wang, Zeng, Wang, Ziyi, Wei, Song, Liu, Mu, Wang, Peng, Qiu, Jiannan, Zhang, Lei, Wu, Chen, Shen, Hongbing, Wang, Xuehao, Cheng, Feng, Lu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664121/
https://www.ncbi.nlm.nih.gov/pubmed/35140065
http://dx.doi.org/10.1136/gutjnl-2021-325150
_version_ 1784831034182860800
author Rao, Jianhua
Wang, Hao
Ni, Ming
Wang, Zeng
Wang, Ziyi
Wei, Song
Liu, Mu
Wang, Peng
Qiu, Jiannan
Zhang, Lei
Wu, Chen
Shen, Hongbing
Wang, Xuehao
Cheng, Feng
Lu, Ling
author_facet Rao, Jianhua
Wang, Hao
Ni, Ming
Wang, Zeng
Wang, Ziyi
Wei, Song
Liu, Mu
Wang, Peng
Qiu, Jiannan
Zhang, Lei
Wu, Chen
Shen, Hongbing
Wang, Xuehao
Cheng, Feng
Lu, Ling
author_sort Rao, Jianhua
collection PubMed
description OBJECTIVE: Follistatin-like protein 1 (FSTL1) is widely recognised as a secreted glycoprotein, but its role in modulating macrophage-related inflammation during liver fibrosis has not been documented. Herein, we aimed to characterise the roles of macrophage FSTL1 in the development of liver fibrosis. DESIGN: Expression analysis was conducted with human liver samples obtained from 33 patients with liver fibrosis and 18 individuals without fibrosis serving as controls. Myeloid-specific FSTL1-knockout (FSTL1(M-KO)) mice were constructed to explore the function and mechanism of macrophage FSTL1 in 3 murine models of liver fibrosis induced by carbon tetrachloride injection, bile duct ligation or a methionine-deficient and choline-deficient diet. RESULTS: FSTL1 expression was significantly elevated in macrophages from fibrotic livers of both humans and mice. Myeloid-specific FSTL1 deficiency effectively attenuated the progression of liver fibrosis. In FSTL1(M-KO) mice, the microenvironment that developed during liver fibrosis showed relatively less inflammation, as demonstrated by attenuated infiltration of monocytes/macrophages and neutrophils and decreased expression of proinflammatory factors. FSTL1(M-KO) macrophages exhibited suppressed proinflammatory M1 polarisation and nuclear factor kappa B pathway activation in vivo and in vitro. Furthermore, this study showed that, through its FK domain, FSTL1 bound directly to the pyruvate kinase M2 (PKM2). Interestingly, FSTL1 promoted PKM2 phosphorylation and nuclear translocation, reduced PKM2 ubiquitination to enhance PKM2-dependent glycolysis and increased M1 polarisation. Pharmacological activation of PKM2 (DASA-58) partially countered FSTL1-mediated glycolysis and inflammation. CONCLUSION: Macrophage FSTL1 promotes the progression of liver fibrosis by inducing M1 polarisation and inflammation based on the intracellular PKM2 reprogramming function of macrophages.
format Online
Article
Text
id pubmed-9664121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96641212022-11-15 FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2 Rao, Jianhua Wang, Hao Ni, Ming Wang, Zeng Wang, Ziyi Wei, Song Liu, Mu Wang, Peng Qiu, Jiannan Zhang, Lei Wu, Chen Shen, Hongbing Wang, Xuehao Cheng, Feng Lu, Ling Gut Hepatology OBJECTIVE: Follistatin-like protein 1 (FSTL1) is widely recognised as a secreted glycoprotein, but its role in modulating macrophage-related inflammation during liver fibrosis has not been documented. Herein, we aimed to characterise the roles of macrophage FSTL1 in the development of liver fibrosis. DESIGN: Expression analysis was conducted with human liver samples obtained from 33 patients with liver fibrosis and 18 individuals without fibrosis serving as controls. Myeloid-specific FSTL1-knockout (FSTL1(M-KO)) mice were constructed to explore the function and mechanism of macrophage FSTL1 in 3 murine models of liver fibrosis induced by carbon tetrachloride injection, bile duct ligation or a methionine-deficient and choline-deficient diet. RESULTS: FSTL1 expression was significantly elevated in macrophages from fibrotic livers of both humans and mice. Myeloid-specific FSTL1 deficiency effectively attenuated the progression of liver fibrosis. In FSTL1(M-KO) mice, the microenvironment that developed during liver fibrosis showed relatively less inflammation, as demonstrated by attenuated infiltration of monocytes/macrophages and neutrophils and decreased expression of proinflammatory factors. FSTL1(M-KO) macrophages exhibited suppressed proinflammatory M1 polarisation and nuclear factor kappa B pathway activation in vivo and in vitro. Furthermore, this study showed that, through its FK domain, FSTL1 bound directly to the pyruvate kinase M2 (PKM2). Interestingly, FSTL1 promoted PKM2 phosphorylation and nuclear translocation, reduced PKM2 ubiquitination to enhance PKM2-dependent glycolysis and increased M1 polarisation. Pharmacological activation of PKM2 (DASA-58) partially countered FSTL1-mediated glycolysis and inflammation. CONCLUSION: Macrophage FSTL1 promotes the progression of liver fibrosis by inducing M1 polarisation and inflammation based on the intracellular PKM2 reprogramming function of macrophages. BMJ Publishing Group 2022-12 2022-02-09 /pmc/articles/PMC9664121/ /pubmed/35140065 http://dx.doi.org/10.1136/gutjnl-2021-325150 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Hepatology
Rao, Jianhua
Wang, Hao
Ni, Ming
Wang, Zeng
Wang, Ziyi
Wei, Song
Liu, Mu
Wang, Peng
Qiu, Jiannan
Zhang, Lei
Wu, Chen
Shen, Hongbing
Wang, Xuehao
Cheng, Feng
Lu, Ling
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title_full FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title_fullStr FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title_full_unstemmed FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title_short FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2
title_sort fstl1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of pkm2
topic Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664121/
https://www.ncbi.nlm.nih.gov/pubmed/35140065
http://dx.doi.org/10.1136/gutjnl-2021-325150
work_keys_str_mv AT raojianhua fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wanghao fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT niming fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wangzeng fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wangziyi fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT weisong fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT liumu fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wangpeng fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT qiujiannan fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT zhanglei fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wuchen fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT shenhongbing fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT wangxuehao fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT chengfeng fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2
AT luling fstl1promotesliverfibrosisbyreprogrammingmacrophagefunctionthroughmodulatingtheintracellularfunctionofpkm2